Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir Intensification on HIV-1 Viral Latency
NCT00554398Phase 3Completed
- Sponsor
- Hospital Universitari Germans Trias i Pujol
- Start
- Nov 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hospital Universitari Germans Trias i Pujol. Primary endpoint: Quantification of integrated and unintegrated viral HIV-1 DNA in PBMCs at 48 weeks. Started Nov 2007; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00554398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00554398.